Abstract
JAKs are a family of intracellular tyrosine kinases consisting of four members, JAK1, JAK2, JAK3, and TYK2. They are key components of the JAK-STAT pathway that transmit signals of many cytokines involved in the pathogenesis of numerous immune-mediated diseases and have been major molecular targets in developing new drugs for the treatment of such diseases. Some small-molecule inhibitors of JAKs have been approved by the FDA for rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease. Now, newer JAK inhibitors with isoform-selectivity among the four different JAKs are being developed, with the aim of improving clinical outcomes compared with earlier developed drugs with pan-JAK inhibition. Most of these selective inhibitors target the kinase domains of JAKs, functioning through the traditional inhibition mode of kinases; but recently those that target their pseudokinase domains, allosterically inhibiting the enzymes, have been under development. In this review, key characteristics, efficacy, and safety of FDA-approved and representative drugs in late stages of development are briefly described in order to provide clinical implications with respect to JAK inhibitor selectivity and future development perspectives. The recent development of pseudokinase-targeted inhibitors of JAKs is also included.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Babon JJ, Lucet IS, Murphy JM, Nicola NA, Varghese LN (2014) The molecular regulation of Janus kinase (JAK) activation. Biochem J 462:1–13. https://doi.org/10.1042/BJ20140712
Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM (2017) JAK-STAT signaling as a target for inflammatory and autoimmune disease: Current and future prospects. Drugs 77:521–546. https://doi.org/10.1007/s40265-017-0701-9
Bechman K, Yates M, Galloway JB (2019) The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors. Pharmacol Res 147:104392. https://doi.org/10.1016/j.phrs.2019.104392
Burke JR, Cheng L, Gillooly KM, Strnad J, Zupa-Fernandez A, Catlett IM, Zhang Y, Heimrich EM, McIntyre KW, Cunningham MD, Carman JA, Zhou X, Banas D, Chaudhry C, Li S, D’Arienzo C, Chimalakonda A, Yang X, Xie JH, Pang J, Zhao Q, Rose SM, Huang J, Moslin RM, Wrobleski ST, Weinstein DS, Salter-Cid LM (2019) Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med 11:eaaw1736. https://doi.org/10.1126/scitranslmed.aaw1736
Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Soma K, Bradley J, Mebus C (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381:451–460. https://doi.org/10.1016/S0140-6736(12)61424-X
Burmester GR, Kremer JM, den Bosch FV, Kivitz A, Bessette L, Li Y, Zhou Y, Othman AA, Pangan AL, Camp HS (2018) Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 391:2503–2512. https://doi.org/10.1016/S0140-6736(18)31115-2
Byrne DP, Foulkes DM, Eyers PA (2017) Pseudokiases: update on their functions and evaluation as new drug targets. Future Med Chem 9:245–265. https://doi.org/10.4155/fmc-2016-0207
Catlett I, Aras U, Liu Y, Bei D, Girgis I, Murthy B, Honczarenko M, Rose S (2017) A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2. Ann Rheum Dis 76:859.1–859.859. https://doi.org/10.1136/annrheumdis-2017-eular.3809
Chang Y, Xu S, Ding K (2019) Tyrosine kinase 2 (TYK2) allosteric inhibitors to treat autoimmune diseases. J Med Chem 62:8951–8952. https://doi.org/10.1021/acs.jmedchem.9b01612
Choy EH (2019) Clinical significance of Janus kinase inhibitor selectivity. Rheumatology 58:953–962. https://doi.org/10.1093/rheumatology/key339
Choy EHS, Miceli-Richard C, González-Gay MA, Sinigaglia L, Schlichting DE, Meszaros G, de la Torre I, Schulze-Koops H (2019) The effect of JAK/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. Clin Exp Rheumatol 37:694–704
Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J (2017) Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5+ years: integrated analysis of data from the global clinical trials. Ann Rheum Dis 76:1253–1262. https://doi.org/10.1136/annrheumdis-2016-210457
Cohen S, van Vollenhoven R, Winthrop K, Zerbini CA, Tanaka Y, Bessette L, Zhang Y, Khan N, Hendrickson B, Enejosa JJ, Burmester G (2019) Safety profile of upadacitinib in rheumatoid arthritis: Integrated analysis from the SELECT phase 3 clinical program. American College of Rheumatology Web. Available at https://acrabstracts.org/abstract/safety-profile-of-upadacitinib-in-rheumatoid-arthritis-integrated-analysis-from-the-select-phase-3-clinical-program/. Accessed 13 Aug 2020
Combe B, Kivitz A, Tanaka Y, van der Heijde D, Matzkies F, Bartok B, Ye L, Guo Y, Tasset C, Sundy J, Mozaffarian N, Landewé R, Bae SC, Keystone E, Nash P. (2019) Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results. American College of Rheumatology Web. Available at https://acrabstracts.org/abstract/efficacy-and-safety-of-filgotinib-for-patients-with-rheumatoid-arthritis-with-inadequate-response-to-methotrexate-finch1-primary-outcome-results/. Accessed August 18 2020
Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, Beattie S, Witt S, de la Torre I, Gaich C, Rooney T, Schlichting D, de Bono S, Emery P (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76:88–95. https://doi.org/10.1136/annrheumdis-2016-210094
Farmer LJ, Ledeboer MW, Hoock T, Arnost MJ, Bethiel RS, Bennani YL, Black JJ, Brummel CL, Chakilam A, Dorsch WA, Fan B, Cochran JE, Halas S, Harrington EM, Hogan JK, Howe D, Huang H, Jacobs DH, Laitinen LM, Liao S, Mahajan S, Marone V, Martinez-Botella G, McCarthy P, Messersmith D, Namchuk M, Oh L, Penny MS, Pierce AC, Raybuck SA, Rugg A, Salituro FG, Saxena K, Shannon D, Shlyakter D, Swenson L, Tian SK, Town C, Wang J, Wang T, Wannamaker MW, Winquist RJ, Zuccola HJ (2015) Discovery of VX-509 (Decernotinib): A potent and selective Janus kinase 3 inhibitor for the treatment of autoimmune diseases. J Med Chem 58:7195–7216. https://doi.org/10.1921/acs.jmedchem.5b00301
FDA (US Food & Drug Administration) (2019) FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). US FDA official website. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and. Accessed 24 Aug 2020
FDA (US Food & Drug Administration) (2020) Novel Drug Approvals for 2019. US FDA official website. Available at https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2019US. Accessed 24 Aug 2020
Fleischmann RM, Damjanov NS, Kivitz AJ, Legedza A, Hoock T, Kinnman N (2015) A randomized, double-Blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheumatol 67:334–343. https://doi.org/10.1002/art.38949
Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS (2012) Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. N Engl J Med 367:495–507. https://doi.org/10.1056/NEJMoa1109071
Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y, Othman AA, Genovese MC (2019) Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol 71:1788–1800. https://doi.org/10.1002/art.41032
Fleischmann R, Schiff M, van der Heijde D, Ramos-Remus C, Spindler A, Stanislav M, Zerbini CAF, Gurbuz S, Dickson C, de Bono S, Schlichting D, Beattie S, Kuo WL, Rooney T, Macias W, Takeuchi T (2017) Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69:506–517. https://doi.org/10.1002/art.39953
Fragoulis GE, McInnes IB, Siebert S (2019) JAK-inhibitors, New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology 58:i43–i54. https://doi.org/10.1093/rheumatology/key276
Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF, Wen X, Shi J, McGee R, Haley PJ, Shepard S, Rodgers JD, Yeleswaram S, Hollis G, Newton RC, Metcalf B, Friedman SM, Vaddi K (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 184:5298–5307. https://doi.org/10.4049/jimmunol.0902819
Gadina M (2013) Janus kinases: An ideal target for the treatment of autoimmune diseases. J Investig Dermatol Symp Proc 16:S70–S72. https://doi.org/10.1038/jidysmp.2013.29
Gadina M, Johnson C, Schwartz D, Bonelli M, Hasni S, Kanno Y, Changelian P, Laurence A, O’Shea JJ (2018) Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. J Leukoc Biol 104:499–514. https://doi.org/10.1002/JLB.5RI0218-084R
Gadina M, Le MT, Schwartz DM, Silvennoinen O, Nakayamada S, Yamaoka K, O’Shea JJ (2019) Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology 58:i4–i16. https://doi.org/10.1093/rheumatology/key432
Gadina M, Schwartz DM, O’Shea JJ (2016) Decernotinib: A next-generation Jakinb. Arthritis Rheumatol 68:31–34. https://doi.org/10.1002/art.39463
Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert-Roth A, Zhang Y, Zhou Y, Mohamed MEF, Meerwein S, Pangan AL (2018) Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 391:2513–2524. https://doi.org/10.1016/S0140-6736(18)31116-4
Genovese MC, Kalunian K, Gottenberg J, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sunday JS, de Vlam K, Walker D, Takeuchi T (2019) Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: The FINCH 2 randomized clinical trial. JAMA 322:315–325. https://doi.org/10.1001/jama.2019.9055
Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, Macias WL, de Bono S, Schlichting DE, Smolen JS (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374:1243–1252. https://doi.org/10.1056/NEJMoa1507247
Genovese M, Smolen J, Takeuchi T, Burmester G, Brinker D, Rooney T, Zhong J, Mo D, Saifan C, Cardoso A, Issa M, Wu WS, Winthrop K. (2019) Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An updated integrated safety analysis. American College of Rheumatology Web. Available at https://acrabstracts.org/abstract/safety-profile-of-baricitinib-for-the-treatment-of-rheumatoid-arthritis-up-to-7-years-an-updated-integrated-safety-analysis/. Accessed August 14 2020
Genovese MC, van Vollenhoven RF, Pacheco-Tena C, Zhang Y, Kinnman N (2016) VX-509 (decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheumatol 68:46–55. https://doi.org/10.1002/art.39473
Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 377:1525–1536. https://doi.org/10.1056/NEJMoa1615977
Graff C, Schwartz A, Voss J, Wishart N, Olson L, George J, Hyland D, Camp H (2014) Characterization of ABT-494, a second generation JAK1 selective inhibitor. American College of Rheumatology Web. Available at https://acrabstracts.org/abstract/characterization-of-abt-494-a-second-generation-jak1-selective-inhibitor/. Accessed 25 Aug 2020
Harigai M (2019) Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology 58:i34–i42. https://doi.org/10.1093/rheumatology/key287
Havnaer A, Weinberg JM, Han G (2019) Systemic therapies in psoriasis: An update on newly approved and pipeline biologics and oral treatments. Cutis 104:17–20
Hirahara K, Schwartz D, Gadina M, Kanno Y, O’Shea JJ (2016) Targeting cytokine signaling in autoimmunity: back to the future and beyond. Curr Opin Immunol 43:89–97. https://doi.org/10.1016/j.coi.2016.10.001
Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, Menon S, Lamba M, Zwillich S (2016) The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 34:318–328
Jamilloux Y, Jammal TE, Vuitton L, Gerfaud-Valentin M, Kerever S, Sève P (2019) JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev 18:102390. https://doi.org/10.1016/j.autrev.2019.102390
Kavanaugh A, Kremer J, Ponce L, Cseuz R, Reshetko OV, Stanislavchuk M, Greenwald M, Van der Aa A, Vanhoutte F, Tasset C, Harrison P (2017) Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis 76:1009–1019. https://doi.org/10.1136/annrheumdis-2016-210105
Kivitz AJ, Cohen S, Keystone E, van Vollenhoven RF, Haraoui B, Kaine J, Fan H, Connell CA, Bananis E, Takiya L, Fleischmann R (2018) A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population. Semin Arthritis Rheum 48:406–415
Kontzias A, Kotlyar A, Laurence A, Changelian P, O’Shea JJ (2012) Jakinibs: A new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol 12:464–470. https://doi.org/10.1016/j.coph.2012.06.008
Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 159:253–261. https://doi.org/10.7326/0003-4819-159-4-201308200-00006
Kung JE, Jura N (2019) Prospects for pharmacological targeting of pseudokinases. Nat Rev Drugs Discov 18:501–526. https://doi.org/10.1038/s41573-019-0018-3
Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377–2386. https://doi.org/10.1056/NEJMoa1310476
Liongue C, Sertori R, Ward AC (2016) Evolution of cytokine receptor signaling. J Immunol 197:11–18. https://doi.org/10.4049/jimmunol.1600372
Liu X, Fang L, Guo TB, Mei H, Zhang JZ (2013) Drug targets in the cytokine universe for autoimmune disease. Trends Immunol 34:120–128. https://doi.org/10.1016/j.it.2012.10.003
Lu X, Smaill JB, Ding K (2020) New promise and opportunities for allosteric kinase inhibitors. Angew Chem Int Ed 59:2–15. https://doi.org/10.1002/anie.201914525
Ly K, Beck KM, Smith MP, Orbai AM, Liao W (2019) Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives. Psoriasis (Auckl) 9:97–107. https://doi.org/10.2147/PTT.S161453
Mahajan S, Hogan JK, Shlyakhter D, Oh L, Salituro FG, Farmer L, Hoock TC (2015) VX-509 (decernotinib) is a potent and selective Janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune diseases. J Pharmacol Exp Ther 353:405–414. https://doi.org/10.1124/jpet.114.221176
Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila–Zapata F, Cieślak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377:1537–1550. https://doi.org/10.1056/NEJMoa1615975
Menet CJ, Fletcher SR, Van Lommen G, Geney R, Blanc J, Smits K, Jouannigot N, Deprez P, van der Aar EM, Clement-Lacroix P, Lepescheux L, Galien R, Vayssiere B, Nelles L, Christophe T, Brys R, Uhring M, Ciesielski F, van Rompaey L (2014) Triazolopyridines as selective JAK1 inhibitors: From hit identification to GLPG0634. J Med Chem 57:9323–9342. https://doi.org/10.1021/jm501262q
Moslin R, Gardner D, Santella J, Zhang Y, Duncia JV, Liu C, Lin J, Tokarski JS, Strnad J, Pedicord D, Chen J, Blat Y, Zupa-Fernandez A, Cheng L, Sun H, Chaudhry C, Huang C, D’Arienzo C, Sack JS, Muckelbauer JK, Chang C, Tredup J, Xie D, Aranibar N, Burke JR, Carter PH, Weinstein DS (2017) Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling. Med Chem Commun 8:700–712. https://doi.org/10.1039/c6md00560h
Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L (2020) Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: A systematic review and meta-analysis. Gastroenteroloy 158:1554–1573. https://doi.org/10.1053/j.gastro.2020.01.001
O’Shea JJ, Holland SM, Staudt LM (2013a) JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368:161–170. https://doi.org/10.1056/NEJMra1202117
O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A (2013b) Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 72:ii111–ii115. https://doi.org/10.1136/annrheumdis-2012-202576
O’Shea JJ, Laurence A, McInnes IB (2013c) Back to the future: Oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol 9:173–182. https://doi.org/10.1038/nrrheum.2013.7
O’Shea JJ, Plenge R (2012) JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 36:542–550. https://doi.org/10.1016/j.immuni.2012.03.014
O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A (2015) The JAK-STAT pathway: Impact on human disease and therapeutic intervention. Annu Rev Med 66:311–328. https://doi.org/10.1046/annurev-med-051113-024537
Papp KA, Gordon KB, Thaçi D, Morita A, Gooderham M, Foley P, Girgis IG, Kundu S, Banerjee S (2018) Efficacy and safety of a potent and highly selective oral tyrosine kinase 2 inhibitor, BMS986165, in patients with moderate-to-severe plaque psoriasis: A phase II, randomized, placebo-controlled trial. American College of Rheumatology Web. Available at https://acrabstracts.org/abstract/efficacy-and-safety-of-a-potent-and-highly-selective-oral-tyrosine-kinase-2-inhibitor-bms-986165-in-patients-with-moderate-to-severe-plaque-psoriasis-a-phase-ii-randomized-placebo-controlled-tria/. Accessed August 2 2020
Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, Camp HS, Padley RJ, George JS, Hyand D, Resebraugh M, Wishart N, Olson L, Long AJ (2018) In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol 2:23. https://doi.org/10.1186/s41927-018-0031-x
Peeva E (2019) Oral Janus kinase inhibitors PF-06700841 and PF-06651600 provide clinically evident therapeutic effect at 4 and 6 weeks in patients with alopecia areata and greater efficacy over 24 weeks in patients with a shorter duration of their current alopecia episode: Results of a randomized phase 2a trial. American Academy of Dermatology Web. Available at https://www.aadhighlights2019.com/articles/jak-inhibitors-pf-06700841-and-pf-06651600/read. Accessed August 25 2020
Pei H, He L, Shao M, Yang Z, Ran Y, Li D, Zhou Y, Tang M, Wang T, Gong Y, Chen X, Yang S, Xiang M, Chen L (2018) Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis. Sci Rep 8:5273. https://doi.org/10.1038/s41598-018-23569-y
Plenge R (2010) GWASs and the age of human as the model organism for autoimmune genetic research. Genome Biol 11:212. https://doi.org/10.1186/gb-2010-11-5-212
Robinson MF, Damjanov N, Stamenkovic B, Radunovic G, Kivitz A, Cox L, Manukyan Z, Banifield C, Saunders M, Chandra D, Vincent MS, Mancuso J, Peeva E, Beebe JS (2020) Efficacy and safety of PF-06651600 (ritlecitinib), a novel JAK3/TEC inhibitor in patients with moderate to severe rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. https://doi.org/10.1002/art.41316
Roskoski R Jr (2016) Janus kinas (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res 111:784–803. https://doi.org/10.1016/j.phrs.2016.07.038
Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 376:1723–1736. https://doi.org/10.1056/NEJMoa1606910
Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ (2017) JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 16:843–862. https://doi.org/10.1038/nrd.2017.201
Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Zhang Y, Damjanov N, Friedman A, Othman AA, Camp HS, Cohen S (2019) Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 393:2303–2311. https://doi.org/10.1016/S0140-6736(19)30419-2
Taylor PC (2019) Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis. Rheumatology 58:i17–i26. https://doi.org/10.1093/rheumatology/key225
Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, del Carmen Morales L, Gonzaga JR, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376:652–662. https://doi.org/10.1056/NEJMoa1608345
Taylor PC, Weinblatt ME, Burmester GR, Rooney TP, Witt S, Walls CD, Issa M, Salinas CA, Saifan C, Zhang X, Cardoso A, González-Gay MA, Takeuchi T (2019) Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol 71:1042–1055. https://doi.org/10.1002/art.40841
Telliez JB, Dowty ME, Wang L, Jussif J, Lin T, Li L, Moy E, Balbo P, Li W, Zhao Y, Crouse K, Dickinson C, Symanowicz P, Hegen M, Banker ME, Vincent F, Unwalla R, Liang S, Gilbert AM, Brown MF, Hayward M, Montgomery J, Yang X, Bauman J, Trujillo JI, Casmiro-Garcia A, Vajdos FF, Leung L, Geoghegan KF, Quazi A, Xuan D, Jones L, Hett E, Wright K, Clark JD, Thorarensen A (2016) Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. ACS Chem Biol 11:3442–3451. https://doi.org/10.1021/acschembio.6b00677
Tokarski JS, Zupa-Fernandez A, Tredup JA, Pike K, Chang CY, Xie D, Cheng L, Pedicord D, Muckelbauer J, Johnson SR, Wu S, Edavettal SC, Hong Y, Witmer MR, Elkin LL, Blat Y, Pitts WJ, Weinstein DS, Burke JR (2015) Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain. J Biol Chem 290:11061–11074. https://doi.org/10.1074/jbc.M114.619502
van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Wyman BT, Gruben D, Benda B, Wallenstein G, Krishnaswami S, Zwillich SH, Bradley JD, Connell CA (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65:559–570. https://doi.org/10.1002/art.37816
van Rompaey L, Galien R, van der Aar EM, Clement-Lacroix P, Nelles L, Smets B, Lepescheux L, Christophe T, Conrath K, Vandeghinste N, Vayssiere B, De Vos S, Fletcher S, Brys R, van’t Klooster G, Feyen JHM, Menet C (2013) Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 191:3568–3577. https://doi.org/10.4049/jimmunol.1201348
van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367:508–519. https://doi.org/10.1056/NEJMoa1112072
van Vollenhoven R, Takeuchi T, Pangan AL, Friedman A, Mohamed MEF, Chen S, Rischmueller M, Blanco R, Xavier RM, Strand V (2020) Efficacy and safety of upadacitinib monotherapy in methotrexate-naïve patients with moderately to severely active rheumatoid arthritis (SELECT‐EARLY): A randomized, double‐blind, active‐comparator, multi‐center, multi‐country trial. Arthritis Rheumatol. https://doi.org/10.1002/art.41384
Varyani F, Argyriou K, Phillips F, Tsakiridou E, Moran GW (2019) Profile of tofacitinib in the treatment of ulcerative colitis: An evidence-based review of recent data. Drug Des Devel Ther 13:4091–4105. https://doi.org/10.2147/DDDT.S182891
Virtanen AT, Haikarainen T, Raivola J, Silvennoinen O (2019) Selective JAKinibs: Prospects in inflammatory and autoimmune diseases. BioDrugs 33:15–32. https://doi.org/10.1007/s40259-019-00333-w
Westhovens R (2019) Clinical efficacy of new JAK inhibitors under development. Just more of the same? Rheumatology 58:i27–i33. https://doi.org/10.1093/rheumatology/key256
Westhovens R, Rigby WFC, van der Heijde D, Ching DWT, Bartok B, Matzkies F, Yin Z, Guo Y, Tasset C, Sundy J, Mozaffarian N, Messina OD, Landewé RBM, Atsumi T, Burmester G (2019) Efficacy and safety of filgotinib for patients with rheumatoid arthritis naïve to methotrexate therapy: FINCH3 primary outcome results. American College of Rheumatology Web. Available at https://acrabstracts.org/abstract/efficacy-and-safety-of-filgotinib-for-patients-with-rheumatoid-arthritis-naive-to-methotrexate-therapy-finch3-primary-outcome-results/. Accessed August 18 2020
Westhovens R, Taylor PC, Alten R, Pavlova D, Enríquez-Sosa F, Mazur M, Greenwald M, Van der Aa A, Vanhoutte F, Tasset C, Harrison P (2017) Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis 76:998–1008. https://doi.org/10.1136/annrheumdis-2016-210104
Winthrop K, Genovese M, Combe B, Tanaka Y, Kivitz A, Matzkies F, Bartok B, Ye L, Guo Y, Tasset C, Sundy J, Keystone E, Westhovens R, Rigby WFC, Burmester G. (2019) Pooled safety analyses from phase 3 studies of filgotinib in patients with rheumatoid arthritis. American College of Rheumatology Web. Available at https://acrabstracts.org/abstract/pooled-safety-analyses-from-phase-3-studies-of-filgotinib-in-patients-with-rheumatoid-arthritis/. Accessed August 14 2020
Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z (2019) Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 78:1043–1054. https://doi.org/10.1136/annrheumdis-2018-214846
Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, Ma H, Wei D, Sun S (2020) The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol 80:106210. https://doi.org/10.1016/j.intimp.2020.106210
Xu P, Shen P, Yu B, Xu X, Ge R, Cheng X, Chen Q, Bian J, Li Z, Wang J (2020) Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. Eur J Med Chem 192:112155. https://doi.org/10.1016/j.ejmech.2020.112155
Acknowledgements
This work was supported by the Konyang University Research Fund in 2019.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
There is no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kim, HO. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors. Arch. Pharm. Res. 43, 1173–1186 (2020). https://doi.org/10.1007/s12272-020-01282-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-020-01282-7